Category: Pα+ - Page 2 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Post published:October 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Q3’25 Investor Survey: What are Investors Most Concerned About?

Q3’25 Investor Survey: What are Investors Most Concerned About?

Post published:October 23, 2025
Post category:Analysis News Pα+

Read more about the article Q3’25 Survey: What are Psychedelics Investors Excited About?

Q3’25 Survey: What are Psychedelics Investors Excited About?

Post published:October 21, 2025
Post category:Analysis News Pα+

Read more about the article September 2025 Psychedelic Patent Update

September 2025 Psychedelic Patent Update

Post published:October 20, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Psychedelic Funding Update: Q3 2025

Psychedelic Funding Update: Q3 2025

Post published:October 16, 2025
Post category:Analysis Pα+

Read more about the article Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Post published:October 14, 2025
Post category:Interviews Pα+

Read more about the article Q2 2025: Oregon Psilocybin Services Update

Q2 2025: Oregon Psilocybin Services Update

Post published:October 10, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I

Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I

Post published:October 3, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Pα+ Psychedelic Bulletin #209: Aussie Insurer Covers Psilocybin for TRD; atai Scores $11.4M NIDA Grant; First Look at Real-World Outcomes from Oregon Psilocybin Clients; Pipeline Updates

Post published:September 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Post published:September 22, 2025
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.